Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice

Vaccine

Volumn 30, Issue 11, 2012, Pages 1911-1916

  Zhou, Mingkui ^a   Kostoula, Ioanna ^b   Brill, Boris ^a   Panou, Eugenia ^b   Sakarellos Daitsiotis, Maria ^b   Dietrich, Ursula ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Epitopes; Gp41; HIV 1; Immunogens; Neutralizing antibodies; Sequential oligopeptide carriers

Indexed keywords

EC26 2A4 EPITOPE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEIN GP41; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; OLIGOPEPTIDE; PALMITOYL ACID; SEQUENTIAL OLIGOPEPTIDE CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MEMBRANE PROXIMAL EXTERNAL REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VACCINATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CHEMISTRY TECHNIQUES, SYNTHETIC; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNIZATION, SECONDARY; MICE; NEUTRALIZATION TESTS;

EID: 84857195490     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.026     Document Type: Article

References (53)

1. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000, 6(2):200-206.
2. Ferrantelli F., Hofmann-Lehmann R., Rasmussen R.A., Wang T., Xu W., Li P.L., et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003, 17(3):301-309.
3. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15(8):951-954.
4. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73(5):4009-4018.
5. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75(17):8340-8347.
6. Ruprecht R.M. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol. Biol. 2009, 525:559-566. xiv.
7. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999, 5(2):204-210.
8. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
9. Burton D.R., Weiss R.A. AIDS/HIV. A boost for HIV vaccine design. Science 2010, 329(5993):770-773.
10. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5(1):e8805.
11. Moore P.L., Gray E.S., Sheward D., Madiga M., Ranchobe N., Lai Z., et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 2011, 85(7):3128-3141.
12. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458(7238):636-640.
13. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., et al. Broad neutralization coverage of HIV-1 by multiple highly potent antibodies. Nature 2011, 477(7365):466-470.
14. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
15. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993):856-861.
16. Johnston M.I., Fauci A.S. HIV vaccine development - improving on natural immunity. N. Engl. J. Med. 2011, 365(10):873-875.
17. Pietzsch J., Scheid J.F., Mouquet H., Seaman M.S., Broder C.C., Nussenzweig M.C. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J. Virol. 2010, 84(10):5032-5042.
18. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308(5730):1906-1908.
19. Haynes B.F., Moody M.A., Verkoczy L., Kelsoe G., Alam S.M. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 2005, 14(3-4):59-67.
20. Zhu Z., Qin H.R., Chen W., Zhao Q., Fouda G., Schutte R., et al. New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope. AIDS Res. Hum. Retroviruses 2010, 26(10):A14-A15.
21. Mehandru S., Wrin T., Galovich J., Stiegler G., Vcelar B., Hurley A., et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J. Virol. 2004, 78(24):14039-14042.
22. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78(23):13232-13252.
23. Shen X., Parks R.J., Montefiori D.C., Kirchherr J.L., Keele B.F., Decker J.M., et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 2009, 83(8):3617-3625.
24. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67(11):6642-6647.
25. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75(22):10892-10905.
26. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994, 68(6):4031-4034.
27. Kargakis M., Zevgiti S., Krikorian D., Sakarellos-Daitsiotis M., Sakarellos C., Panou-Pomonis E. A palmitoyl-tailed sequential oligopeptide carrier for engineering immunogenic conjugates. Vaccine 2007, 25(37-38):6708-6712.
28. Alexopoulos C., Sakarellos-Daitsiotis M., Sakarellos C. Synthetic carriers: sequential oligopeptide carriers SOCn-I and SOCn-II as an innovative and multifunctional approach. Curr. Med. Chem. 2005, 12(13):1469-1479.
29. Sakarellos-Daitsiotis M., Tsikaris V., Sakarellos C., Vlachoyiannopoulos P.G., Tzioufas A.G., Moutsopoulos H.M. A new helicoid-type sequential oligopeptide carrier (SOC(n)) for developing potent antigens and immunogens. Vaccine 2000, 18(3-4):302-310.
30. Sakarellos-Daitsiotis M., Alexopoulos C., Sakarellos C. Sequential oligopeptide carriers, SOCn, as scaffolds for the reconstitution of antigenic proteins: applications in solid phase immunoassays. J. Pharm. Biomed. Anal. 2004, 34(4):761-769.
31. Skarlas T., Zevgiti S., Droebner K., Panou-Pomonis E., Planz O., Sakarellos-Daitsiotis M. Influenza virus H5N1 hemagglutinin (HA) T-cell epitope conjugates: design, synthesis and immunogenicity. J. Pept. Sci. 2011, 17(3):226-232.
32. Humbert M., Rasmussen R.A., Ong H., Kaiser F.M., Hu S.L., Ruprecht R.M. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One 2008, 3(12):e3937.
33. Zolla-Pazner S., Cohen S., Pinter A., Krachmarov C., Wrin T., Wang S., et al. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009, 392(1):82-93.
34. Giralt E., Albericio F. Synthesis of peptides on solid supports. Synthesis of Peptides and Peptidomimetics Stuttgard 2003, 665-824. Georg Thieme Verlag, New York. J. Galovich (Ed.).
35. Rose K., Zeng W., Brown L.E., Jackson D.C. A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Mol. Immunol. 1995, 32(14-15):1031-1037.
36. Spetzler J.C., Tam J.P. Unprotected peptides as building blocks for branched peptides and peptide dendrimers. Int. J. Pept. Protein Res. 1995, 45(1):78-85.
37. Papas S., Strongylis C., Tsikaris V. Synthetic Approaches for Total Chemical Synthesis of Proteins and Protein-Like Macromolecules of Branched Architecture. Curr. Org. Chem. 2006, 10(14):1727-1744.
38. Zwick M.B., Bonnycastle L.L., Noren K.A., Venturini S., Leong E., Barbas C.F., et al. The maltose-binding protein as a scaffold for monovalent display of peptides derived from phage libraries. Anal. Biochem. 1998, 264(1):87-97.
39. ® immunostimulant: adjuvant formulations. Vaccine adjuvants: preparation methods and research protocols 2000, p. 273-82.
40. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 2009, 485:395-405.
41. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5(3):233-236.
42. Humbert M., Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev. 2006, 8(2):51-59.
43. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(5187):1024-1027.
44. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17(18):1757-1765.
45. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78(19):10724-10737.
46. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293(5532):1155-1159.
47. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22(2):163-173.
48. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82(23):11651-11668.
49. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007, 81(12):6548-6562.
50. Sather D.N., Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010, 28(Suppl 2):B8-B12.
51. Humbert M., Antoni S., Brill B., Landersz M., Rodes B., Soriano V., et al. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur. J. Immunol. 2007, 37(2):501-515.
52. Sakarellos-Daitsiotis M., Krikorian D., Panou-Pomonis E., Sakarellos C. Artificial carriers: a strategy for constructing antigenic/immunogenic conjugates. Curr. Top. Med. Chem. 2006, 6(16):1715-1735.
53. Matoba N., Shah N.R., Mor T.S. Humoral immunogenicity of an HIV-1 envelope residue 649-684 membrane-proximal region peptide fused to the plague antigen F1-V. Vaccine 2011, 29(34):5584-5590.